The relative proportion of comorbidities among rhinitis and rhinosinusitis patients and their impact on visit burden. Issue 7 (21st July 2022)

• Record Type: Journal Article
• Authors: Nuutinen, Mikko; Lyly, Annina; Virkkula, Paula; Hytönen, Maija; Saarentaus, Elmo; Mäkitie, Antti; Palotie, Aarno; Torkki, Paulus; Haukka, Jari; Toppila‐Salmi, Sanna
• Is Part Of: Clinical and translational allergy. Volume 12:Issue 7(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-07-21
• Subjects: allergy -- asthma -- chronic rhinosinusitis -- non‐steroidal anti‐inflammatory drug exacerbated respiratory disease -- rhinitis; Allergy -- Periodicals; Immunology -- Periodicals; Allergy and Immunology -- Periodicals; Hypersensitivity -- Periodicals; Immune System Phenomena -- Periodicals; 616.97005
• DOI: 10.1002/clt2.12181
• Languages: English
• ISSNs: 2045-7022

Abstract

Abstract: Background: The aim was to evaluate the relative proportion of Non‐steroidal anti‐inflammatory drug exacerbated respiratory disease (NERD) and other comorbidities, and their impact on the burden of outpatient visits due to allergic rhinitis (AR), non‐allergic rhinitis (NAR), acute rhinosinusitis (ARS), and chronic rhinosinusitis with nasal polyps (CRSwNP) and without (CRSsNP). Methods: We used hospital registry data of a random sample of 5080 rhinitis/rhinosinusitis patients diagnosed during 2005–2019. International Statistical Classification of Diseases and Related Health Problems (ICD10) diagnoses, visits, and other factors were collected from electronic health records by using information extraction and data processing methods. Cox's proportional hazards model was used for modeling the time to the next outpatient visit. Results: The mean (±standard deviation) age of the population was 33.6 (±20.7) years and 56.1% were female. The relative proportion of AR, NAR, ARS, CRSsNP and CRSwNP, were 33.5%, 27.5%, 27.2%, 20.7%, and 10.9%, respectively. The most common other comorbidities were asthma (44.4%), other chronic respiratory diseases (38.5%), musculoskeletal diseases (38.4%), and cardiovascular diseases (35.7%). Non‐steroidal anti‐inflammatory drug exacerbated respiratory disease existed in 3.9% of all patients, and 17.7% of the CRSwNP group. The relative proportion of subjects having 1, 2, 3 and ≥ 4 other diseases were 18.0%, 17.6%, 17.0%, 37.0%, respectively. All diseases except AR, ARS, and mouth breathing, were associated with a high frequency of outpatient visits. Conclusions: Our results revealed a high relative proportion of NERD and other comorbidities, which affect the burden of outpatient visits and hence confirm the socioeconomic impact of upper airway diseases.